ALX Oncology raises $105 million in Series C financing for CD47 trials

By Akshay Kedari  Date: 2020-02-14

ALX Oncology raises $105 million in Series C financing for CD47 trials

ALX Oncology, a clinical-stage biotechnology company, has secured $105 million in a Series C funding round, led by Vivo Capital. The new investors, who participated in the funding round include Janus Henderson, Logos Capital, Foresite Capital, BVF Partners, HBM Healthcare Investments, and Cormorant Asset Management. The Series C funding round also witnessed the participation of existing investors Lightstone Ventures and Existing investors venBio, who had participated in the previous two rounds.

The latest funds will be used to further phase 2 study of CD47 myeloid checkpoint inhibitor ALX148 along with other anti-cancer treatments. The Series C funding round comes after the revelation of data by ALX on patients suffering from relapsed or refractory non-Hodgkin lymphoma (NHL), who have been treated using ALX148 in combination with rituximab. Among the 21 evaluable subjects, the company observed a median progression-free survival of 7.3 months and an objective response rate of around 43%. The drug was noted to be well tolerated and relatively safe.

Corey Goodman, Co-Founder and Executive Chairman, ALX, reportedly stated that from the initial days, the company believed that it will be the best-in-class in the CD47 checkpoint pathway by utilizing a ‘dead’ Fc domain that does not bind to macrophages, thus lessening the cytopenias and other toxicities related to this class of agents. The company is elated to observe the clinical results supporting its hypothesis and offering the opportunity for higher dosing and increased efficacy, he further added.

The phase 1 study, that generated the lymphoma data is progressing with other arms of the trial testing the potential of CD47 in combination with Keytruda and Herceptin in patients suffering from a solid tumor. But, with ALX148 coming through its first trial in NHL, ALX intends to take the candidate deeper into the clinic. The series C financing proceeds will be used to bankroll the further development of ALX148. 
 

Source links:

https://www.fiercebiotech.com/biotech/alx-raises-105m-for-midphase-trials-cd47-cancer-drug

 

About Author

Akshay Kedari     aeresearch.net

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More

More News By Akshay Kedari

Apple’s iPhone 13 production may take a hit due to global chip shortage

Apple’s iPhone 13 production may take a hit due to global chip shortage

By Akshay Kedari

Apple Inc. is likely to cut down production of its iPhone 13 model by approximately 10 million units on account of the global chip shortage. The American multinational technology company was previously expected to manufacture 90 million units of the ...

Israel's GoTo Global acquires German e-moped sharing platform emmy

Israel's GoTo Global acquires German e-moped sharing platform emmy

By Akshay Kedari

Israel-based multimodal vehicle sharing services provider GoTo Global Mobility Ltd. has reportedly acquired Germany’s shared e-scooter company emmy. The acquisition will allow GoTo Global to enter the German market as well as accelerate its Eur...

German airline Lufthansa adds four new planes to its A350 fleet

German airline Lufthansa adds four new planes to its A350 fleet

By Akshay Kedari

Deutsche Lufthansa AG recently revealed that it has agreed to take four new Airbus A350-900 long-haul passenger aircraft on lease, utilizing newer planes that are left grounded as airlines reorganize their balance sheets in the wake of the ...

Samsung fined USD 47 million by Dutch watchdog for price-fixing TVs

Samsung fined USD 47 million by Dutch watchdog for price-fixing TVs

By Akshay Kedari

South Korean electronics manufacturing giant Samsung Electronics Co. Ltd. has been charged a penalty of USD 46.9 million by the Dutch competition watchdog Authority for Consumers and Markets (ACM) for price-fixing practices in the Netherlands. The m...

TEA-Lab, MED-EL unveil the world's first multifunction hearing aid app

TEA-Lab, MED-EL unveil the world's first multifunction hearing aid app

By Akshay Kedari

Communication solution provider for cloud meetings Tencent Ethereal Audio Lab (TEA-Lab) together with Austria-quartered implantable hearing solutions leader MED-EL recently announced the launched a first-of-its-kind hearing aid app that incorporates ...